{ "ticker": "BSX", "cik": "0000885725", "company": "Boston Scientific Corporation", "business_type": "industrial", "schema_template": "standard (industrial/medical devices): net sales, cost of products sold, gross profit, operating expenses, operating income, net income, EPS; cash, debt, assets, equity; operating cash flow, capital expenditures, free cash flow; plus net sales by reportable segment, business and region", "reporting_currency": "USD", "converted_to_usd": false, "units": "actual US dollars (not millions); share counts in actual shares; per-share amounts in US dollars", "units_notes_seen": { "FY2025 10-K consolidated statements of operations": "(in millions, except per share data)", "FY2025 10-K consolidated balance sheets": "(in millions, except share and per share data)", "FY2025 10-K consolidated statements of stockholders' equity": "(in millions, except share data)", "FY2025 10-K consolidated statements of cash flows": "(in millions)", "FY2025 10-K Note N - Revenue (net sales by business and region)": "(in millions)", "Q3 2026 10-Q consolidated statements of operations": "(in millions, except per share data)", "Q3 2026 10-Q consolidated balance sheets": "(in millions, except share and per share data)", "Q3 2026 10-Q consolidated statements of stockholders' equity": "(in millions, except share data)", "Q3 2026 10-Q consolidated statements of cash flows": "(in millions)", "Q3 2026 10-Q Note K - Revenue (net sales by business and region)": "(in millions)" }, "adjustments": { "splits_applied": [], "adr_ratio": null, "fx": null, "explanation": "None required: Boston Scientific is a US domestic filer reporting in US dollars, its common stock trades directly on the NYSE (no ADR), and there has been no stock split in the periods presented. Per-share figures are as the filings print them." }, "annual": [ { "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0000885725-26-000010", "fiscal_year": 2025, "income_statement": { "net_sales": 20074000000, "cost_of_sales": 6221000000, "gross_profit": 13854000000, "selling_general_and_administrative_expenses": 6887000000, "research_and_development_expenses": 2052000000, "royalty_expense": 46000000, "amortization_expense": 897000000, "intangible_asset_impairment_charges": 46000000, "contingent_consideration_net_expense": 18000000, "restructuring_net_charges": 101000000, "litigation_related_net_charges": 194000000, "total_operating_expenses": 10241000000, "operating_income": 3613000000, "interest_expense": -349000000, "other_income_expense_net": 121000000, "income_before_income_taxes": 3385000000, "income_tax_expense": 493000000, "net_income": 2892000000, "net_income_attributable_to_noncontrolling_interests": -6000000, "net_income_attributable_to_common_stockholders": 2898000000, "basic_shares": 1480400000, "diluted_shares": 1494500000, "basic_eps": 1.96, "diluted_eps": 1.94, "preferred_stock_dividends": 0 }, "balance_sheet": { "cash_and_cash_equivalents": 1965000000, "trade_accounts_receivable_net": 2926000000, "inventories": 2943000000, "total_current_assets": 8794000000, "property_plant_and_equipment_net": 4036000000, "goodwill": 18282000000, "other_intangible_assets_net": 7019000000, "total_assets": 43673000000, "current_debt_obligations": 299000000, "accounts_payable": 1144000000, "total_current_liabilities": 5439000000, "long_term_debt": 11137000000, "deferred_tax_liabilities": 220000000, "other_long_term_liabilities": 2405000000, "total_stockholders_equity": 24233000000, "noncontrolling_interests": 239000000, "total_equity": 24472000000, "total_debt": 11436000000, "total_liabilities": 19201000000 }, "cash_flow": { "depreciation_and_amortization": 1368000000, "stock_based_compensation": 299000000, "operating_cash_flow": 4534000000, "capital_expenditures": -876000000, "acquisitions_of_businesses_net_of_cash_acquired": -1593000000, "investments_and_acquisitions_of_certain_technologies": -254000000, "investing_cash_flow": -2640000000, "financing_cash_flow": -395000000, "repurchase_of_common_stock": 0, "free_cash_flow": 3658000000 }, "net_sales_by_business": { "endoscopy": 2916000000, "urology": 2709000000, "neuromodulation": 1199000000, "interventional_cardiology_and_vascular_therapies": 4639000000, "watchman": 1958000000, "electrophysiology": 3325000000, "cardiac_rhythm_management": 2332000000, "interventional_oncology_and_embolization": 996000000 }, "net_sales_by_segment": { "medsurg": 6824000000, "cardiovascular": 13250000000 }, "net_sales_by_region": { "united_states": 12864000000, "europe_middle_east_and_africa": 3451000000, "asia_pacific": 3080000000, "latin_america_and_canada": 678000000 }, "source_filing": "Form 10-K for fiscal year 2025 (accession 0000885725-26-000010), filed 2026-02-17" }, { "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0000885725-26-000010", "fiscal_year": 2024, "income_statement": { "net_sales": 16747000000, "cost_of_sales": 5257000000, "gross_profit": 11490000000, "selling_general_and_administrative_expenses": 5984000000, "research_and_development_expenses": 1615000000, "royalty_expense": 33000000, "amortization_expense": 856000000, "intangible_asset_impairment_charges": 386000000, "contingent_consideration_net_expense": -5000000, "restructuring_net_charges": 16000000, "total_operating_expenses": 8887000000, "operating_income": 2603000000, "interest_expense": -305000000, "other_income_expense_net": -16000000, "income_before_income_taxes": 2282000000, "income_tax_expense": 436000000, "net_income": 1846000000, "net_income_attributable_to_noncontrolling_interests": -8000000, "net_income_attributable_to_common_stockholders": 1853000000, "basic_shares": 1471500000, "diluted_shares": 1485900000, "basic_eps": 1.26, "diluted_eps": 1.25, "litigation_related_net_charges": 0, "preferred_stock_dividends": 0 }, "balance_sheet": { "cash_and_cash_equivalents": 414000000, "trade_accounts_receivable_net": 2558000000, "inventories": 2810000000, "total_current_assets": 6920000000, "property_plant_and_equipment_net": 3294000000, "goodwill": 17089000000, "other_intangible_assets_net": 6684000000, "total_assets": 39395000000, "current_debt_obligations": 1778000000, "accounts_payable": 960000000, "total_current_liabilities": 6399000000, "long_term_debt": 8968000000, "deferred_tax_liabilities": 155000000, "other_long_term_liabilities": 1870000000, "total_stockholders_equity": 21770000000, "noncontrolling_interests": 233000000, "total_equity": 22003000000, "total_debt": 10746000000, "total_liabilities": 17392000000 }, "cash_flow": { "depreciation_and_amortization": 1269000000, "stock_based_compensation": 266000000, "operating_cash_flow": 3435000000, "capital_expenditures": -790000000, "acquisitions_of_businesses_net_of_cash_acquired": -4640000000, "investments_and_acquisitions_of_certain_technologies": -280000000, "investing_cash_flow": -5687000000, "financing_cash_flow": 1814000000, "repurchase_of_common_stock": 0, "free_cash_flow": 2645000000 }, "net_sales_by_business": { "endoscopy": 2687000000, "urology": 2200000000, "neuromodulation": 1106000000, "interventional_cardiology_and_vascular_therapies": 4199000000, "watchman": 1516000000, "electrophysiology": 1904000000, "cardiac_rhythm_management": 2279000000, "interventional_oncology_and_embolization": 856000000 }, "net_sales_by_segment": { "medsurg": 5993000000, "cardiovascular": 10755000000 }, "net_sales_by_region": { "united_states": 10210000000, "europe_middle_east_and_africa": 3228000000, "asia_pacific": 2686000000, "latin_america_and_canada": 624000000 }, "source_filing": "Form 10-K for fiscal year 2025 (accession 0000885725-26-000010), filed 2026-02-17" }, { "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0000885725-26-000010", "fiscal_year": 2023, "income_statement": { "net_sales": 14240000000, "cost_of_sales": 4345000000, "gross_profit": 9896000000, "selling_general_and_administrative_expenses": 5190000000, "research_and_development_expenses": 1414000000, "royalty_expense": 46000000, "amortization_expense": 828000000, "intangible_asset_impairment_charges": 58000000, "contingent_consideration_net_expense": 58000000, "restructuring_net_charges": 69000000, "litigation_related_net_charges": -111000000, "total_operating_expenses": 7553000000, "operating_income": 2343000000, "interest_expense": -265000000, "other_income_expense_net": -93000000, "income_before_income_taxes": 1985000000, "income_tax_expense": 393000000, "net_income": 1592000000, "preferred_stock_dividends": -23000000, "net_income_attributable_to_noncontrolling_interests": -1000000, "net_income_attributable_to_common_stockholders": 1570000000, "basic_shares": 1453000000, "diluted_shares": 1463500000, "basic_eps": 1.08, "diluted_eps": 1.07 }, "cash_flow": { "depreciation_and_amortization": 1196000000, "stock_based_compensation": 233000000, "operating_cash_flow": 2503000000, "capital_expenditures": -711000000, "acquisitions_of_businesses_net_of_cash_acquired": -1811000000, "investments_and_acquisitions_of_certain_technologies": -89000000, "investing_cash_flow": -2574000000, "financing_cash_flow": 5000000, "repurchase_of_common_stock": 0, "free_cash_flow": 1792000000 }, "net_sales_by_business": { "endoscopy": 2482000000, "urology": 1964000000, "neuromodulation": 976000000, "interventional_cardiology_and_vascular_therapies": 3791000000, "watchman": 1274000000, "electrophysiology": 800000000, "cardiac_rhythm_management": 2218000000, "interventional_oncology_and_embolization": 736000000 }, "net_sales_by_segment": { "medsurg": 5422000000, "cardiovascular": 8819000000 }, "net_sales_by_region": { "united_states": 8425000000, "europe_middle_east_and_africa": 2856000000, "asia_pacific": 2400000000, "latin_america_and_canada": 560000000 }, "source_filing": "Form 10-K for fiscal year 2025 (accession 0000885725-26-000010), filed 2026-02-17", "coverage_note": "The FY2025 10-K prints income statement and cash flow statement columns for 2023 but no balance sheet as of December 31, 2023, so FY2023 carries no balance sheet." } ], "quarterly": [ { "label": "Q3 FY2026", "period_start": "2026-07-01", "period_end": "2026-09-30", "period_type": "three months", "source_accession": "0000885725-26-000070", "fiscal_year": 2026, "fiscal_quarter": 3, "income_statement": { "net_sales": 5138000000, "cost_of_sales": 1710000000, "gross_profit": 3428000000, "selling_general_and_administrative_expenses": 1683000000, "research_and_development_expenses": 520000000, "royalty_expense": 12000000, "amortization_expense": 234000000, "intangible_asset_impairment_charges": 39000000, "contingent_consideration_net_expense": -32000000, "restructuring_net_charges": 63000000, "litigation_related_net_charges": 81000000, "total_operating_expenses": 2600000000, "operating_income": 828000000, "interest_expense": -100000000, "other_income_expense_net": 4000000, "income_before_income_taxes": 733000000, "income_tax_expense": 153000000, "net_income": 580000000, "net_income_attributable_to_noncontrolling_interests": -2000000, "net_income_attributable_to_common_stockholders": 582000000, "basic_shares": 1448700000, "diluted_shares": 1452000000, "basic_eps": 0.4, "diluted_eps": 0.4 }, "balance_sheet": { "cash_and_cash_equivalents": 609000000, "trade_accounts_receivable_net": 3113000000, "inventories": 3317000000, "total_current_assets": 8164000000, "other_investments": 2292000000, "property_plant_and_equipment_net": 4183000000, "goodwill": 18736000000, "other_intangible_assets_net": 6860000000, "total_assets": 45461000000, "current_debt_obligations": 1044000000, "accounts_payable": 1250000000, "total_current_liabilities": 5982000000, "long_term_debt": 10909000000, "deferred_tax_liabilities": 264000000, "other_long_term_liabilities": 2434000000, "total_stockholders_equity": 25630000000, "noncontrolling_interests": 243000000, "total_equity": 25873000000, "total_debt": 11953000000, "total_liabilities": 19589000000 }, "net_sales_by_business": { "endoscopy": 741000000, "urology": 661000000, "neuromodulation": 331000000, "interventional_cardiology_and_vascular_therapies": 1273000000, "watchman": 482000000, "electrophysiology": 816000000, "cardiac_rhythm_management": 568000000, "interventional_oncology_and_embolization": 267000000 }, "net_sales_by_segment": { "medsurg": 1733000000, "cardiovascular": 3406000000 }, "net_sales_by_region": { "united_states": 3309000000, "europe_middle_east_and_africa": 829000000, "asia_pacific": 797000000, "latin_america_and_canada": 203000000 }, "source_filing": "Form 10-Q for the quarter ended September 30, 2026 (accession 0000885725-26-000070), filed 2026-11-02", "coverage_note": "Balance sheet is as of September 30, 2026. The 10-Q prints cash flows only for the nine months, so this quarter carries no three-month cash flow figures (see the year_to_date block)." }, { "label": "Q3 FY2025", "period_start": "2025-07-01", "period_end": "2025-09-30", "period_type": "three months", "source_accession": "0000885725-26-000070", "fiscal_year": 2025, "fiscal_quarter": 3, "income_statement": { "net_sales": 5065000000, "cost_of_sales": 1523000000, "gross_profit": 3542000000, "selling_general_and_administrative_expenses": 1741000000, "research_and_development_expenses": 514000000, "royalty_expense": 12000000, "amortization_expense": 225000000, "intangible_asset_impairment_charges": 0, "contingent_consideration_net_expense": 11000000, "restructuring_net_charges": -8000000, "total_operating_expenses": 2494000000, "operating_income": 1048000000, "interest_expense": -87000000, "other_income_expense_net": -23000000, "income_before_income_taxes": 939000000, "income_tax_expense": 183000000, "net_income": 755000000, "net_income_attributable_to_noncontrolling_interests": 0, "net_income_attributable_to_common_stockholders": 755000000, "basic_shares": 1481700000, "diluted_shares": 1495500000, "basic_eps": 0.51, "diluted_eps": 0.51, "litigation_related_net_charges": 0 }, "net_sales_by_business": { "endoscopy": 747000000, "urology": 682000000, "neuromodulation": 293000000, "interventional_cardiology_and_vascular_therapies": 1135000000, "watchman": 512000000, "electrophysiology": 865000000, "cardiac_rhythm_management": 578000000, "interventional_oncology_and_embolization": 253000000 }, "net_sales_by_segment": { "medsurg": 1722000000, "cardiovascular": 3343000000 }, "net_sales_by_region": { "united_states": 3294000000, "europe_middle_east_and_africa": 793000000, "asia_pacific": 802000000, "latin_america_and_canada": 175000000 }, "source_filing": "Form 10-Q for the quarter ended September 30, 2026 (accession 0000885725-26-000070), filed 2026-11-02", "coverage_note": "Year-ago comparative quarter from the Q3 2026 10-Q income statement. The 10-Q prints no balance sheet as of September 30, 2025 and no three-month cash flows, so this quarter carries income statement and net sales detail only." } ], "year_to_date": { "label": "Nine months ended September 30, 2026", "period_start": "2026-01-01", "period_end": "2026-09-30", "period_type": "nine months", "source_accession": "0000885725-26-000070", "prior_year_comparative": { "label": "Nine months ended September 30, 2025", "period_start": "2025-01-01", "period_end": "2025-09-30", "period_type": "nine months", "source_accession": "0000885725-26-000070", "income_statement": { "net_sales": 14788000000, "cost_of_sales": 4613000000, "gross_profit": 10175000000, "selling_general_and_administrative_expenses": 5053000000, "research_and_development_expenses": 1483000000, "royalty_expense": 40000000, "amortization_expense": 669000000, "intangible_asset_impairment_charges": 46000000, "contingent_consideration_net_expense": 11000000, "restructuring_net_charges": 85000000, "total_operating_expenses": 7387000000, "operating_income": 2788000000, "interest_expense": -259000000, "other_income_expense_net": 156000000, "income_before_income_taxes": 2685000000, "income_tax_expense": 463000000, "net_income": 2222000000, "net_income_attributable_to_noncontrolling_interests": -4000000, "net_income_attributable_to_common_stockholders": 2226000000, "basic_shares": 1479600000, "diluted_shares": 1494000000, "basic_eps": 1.5, "diluted_eps": 1.49, "litigation_related_net_charges": 0 }, "cash_flow": { "depreciation_and_amortization": 1003000000, "stock_based_compensation": 228000000, "operating_cash_flow": 3170000000, "capital_expenditures": -525000000, "acquisitions_of_businesses_net_of_cash_acquired": -1504000000, "investments_and_acquisitions_of_certain_technologies": -240000000, "investing_cash_flow": -2128000000, "financing_cash_flow": -211000000, "repurchase_of_common_stock": 0, "free_cash_flow": 2645000000 }, "net_sales_by_business": { "endoscopy": 2157000000, "urology": 1992000000, "neuromodulation": 866000000, "interventional_cardiology_and_vascular_therapies": 3437000000, "watchman": 1423000000, "electrophysiology": 2435000000, "cardiac_rhythm_management": 1746000000, "interventional_oncology_and_embolization": 733000000 }, "net_sales_by_segment": { "medsurg": 5015000000, "cardiovascular": 9773000000 }, "net_sales_by_region": { "united_states": 9479000000, "europe_middle_east_and_africa": 2518000000, "asia_pacific": 2292000000, "latin_america_and_canada": 499000000 }, "source_filing": "Form 10-Q for the quarter ended September 30, 2026 (accession 0000885725-26-000070), prior-year column" }, "income_statement": { "net_sales": 15784000000, "cost_of_sales": 4894000000, "gross_profit": 10890000000, "selling_general_and_administrative_expenses": 5266000000, "research_and_development_expenses": 1589000000, "royalty_expense": 37000000, "amortization_expense": 699000000, "intangible_asset_impairment_charges": 39000000, "contingent_consideration_net_expense": -78000000, "restructuring_net_charges": 74000000, "litigation_related_net_charges": 157000000, "total_operating_expenses": 7783000000, "operating_income": 3107000000, "interest_expense": -285000000, "other_income_expense_net": 133000000, "income_before_income_taxes": 2955000000, "income_tax_expense": 132000000, "net_income": 2823000000, "net_income_attributable_to_noncontrolling_interests": -6000000, "net_income_attributable_to_common_stockholders": 2830000000, "basic_shares": 1468000000, "diluted_shares": 1473900000, "basic_eps": 1.93, "diluted_eps": 1.92 }, "cash_flow": { "depreciation_and_amortization": 1067000000, "stock_based_compensation": 242000000, "operating_cash_flow": 2870000000, "capital_expenditures": -552000000, "acquisitions_of_businesses_net_of_cash_acquired": -930000000, "investments_and_acquisitions_of_certain_technologies": -1801000000, "investing_cash_flow": -2984000000, "repurchase_of_common_stock": -2000000000, "financing_cash_flow": -1239000000, "free_cash_flow": 2318000000 }, "net_sales_by_business": { "endoscopy": 2270000000, "urology": 1991000000, "neuromodulation": 990000000, "interventional_cardiology_and_vascular_therapies": 3850000000, "watchman": 1496000000, "electrophysiology": 2637000000, "cardiac_rhythm_management": 1732000000, "interventional_oncology_and_embolization": 818000000 }, "net_sales_by_segment": { "medsurg": 5252000000, "cardiovascular": 10532000000 }, "net_sales_by_region": { "united_states": 10019000000, "europe_middle_east_and_africa": 2692000000, "asia_pacific": 2479000000, "latin_america_and_canada": 594000000 }, "source_filing": "Form 10-Q for the quarter ended September 30, 2026 (accession 0000885725-26-000070)" }, "trailing_twelve_months": { "label": "Twelve months ended September 30, 2026", "period_start": "2025-10-01", "period_end": "2026-09-30", "period_type": "trailing twelve months", "source_accession": "0000885725-26-000070", "income_statement": { "net_sales": 21070000000, "cost_of_sales": 6502000000, "gross_profit": 14569000000, "selling_general_and_administrative_expenses": 7100000000, "research_and_development_expenses": 2158000000, "operating_income": 3932000000, "income_before_income_taxes": 3655000000, "income_tax_expense": 162000000, "net_income": 3493000000, "net_income_attributable_to_common_stockholders": 3502000000 }, "cash_flow": { "operating_cash_flow": 4234000000, "capital_expenditures": -903000000, "free_cash_flow": 3331000000 }, "derivation": "Derived, not printed: fiscal year 2025 (10-K, accession 0000885725-26-000010) plus nine months ended September 30, 2026, less nine months ended September 30, 2025 (both from the 10-Q, accession 0000885725-26-000070). Per-share amounts and share counts are not given because the filings print no twelve-month figure for them.", "source_accessions": [ "0000885725-26-000010", "0000885725-26-000070" ] }, "notes": [ "Template: standard industrial template, which fits a medical device manufacturer. The company reports two segments, MedSurg and Cardiovascular; net sales by segment, by business and by region are taken from the revenue notes (Note N in the FY2025 10-K, Note K in the Q3 2026 10-Q) on a reported basis. In the fourth quarter of 2025 the legacy Cardiology and Peripheral Interventions businesses were combined into a single Cardiovascular business, and the 10-K revised prior periods to the new structure, so 2023 and 2024 segment figures here are on the revised basis. Segment, business and region amounts can differ from the consolidated total by $1 million because the filings round each line separately.", "Periods: fiscal years 2025, 2024 and 2023 (income statement and cash flows) and year-end balance sheets for 2025 and 2024 come from the FY2025 10-K (accession 0000885725-26-000010). The quarter ended September 30, 2026, the year-ago quarter ended September 30, 2025, the September 30, 2026 balance sheet and the nine-month year-to-date figures come from the Q3 2026 10-Q (accession 0000885725-26-000070). Fiscal years end December 31.", "cost_of_sales is the line the company calls 'Cost of products sold (excluding amortization expense)'. Gross profit is therefore before amortization of acquired intangible assets, which the company reports as a separate operating expense (amortization_expense).", "Signs follow the statements: expenses are positive; interest_expense, capital_expenditures, acquisition payments and other cash outflows are negative. A negative contingent_consideration_net_expense, restructuring_net_charges or litigation_related_net_charges is a net credit. A negative net_income_attributable_to_noncontrolling_interests is a loss attributable to noncontrolling interests, which is why net income attributable to Boston Scientific common stockholders is slightly higher than net income in those periods.", "Diluted EPS is struck on net income attributable to Boston Scientific common stockholders. Share counts are weighted averages, printed in millions in the filings and stored here as actual shares.", "Zeros: where a statement prints a dash, the figure is recorded as zero (litigation-related net charges in FY2024, Q3 2025 and the nine months of 2025; preferred stock dividends in FY2024 and FY2025; share repurchases in the nine months of 2025). The FY2025 10-K cash flow statement has no share repurchase line, and its statement of stockholders' equity shows no repurchase of common stock in 2023, 2024 or 2025, so annual repurchases are recorded as zero. The $23 million of preferred stock dividends in FY2023 preceded the conversion of the company's mandatory convertible preferred stock into common stock during 2023, shown in the statement of stockholders' equity; no preferred shares were outstanding at the end of 2023, 2024 or 2025.", "total_debt is derived as current debt obligations plus long-term debt, both as printed on the balance sheet. total_liabilities is derived as the sum of the printed liability lines (total current liabilities, long-term debt, deferred tax liabilities and other long-term liabilities), because the company prints no total liabilities line. At September 30, 2026 that sum is $19,589 million while total assets less total equity is $19,588 million; the $1 million gap is rounding, which the filing flags ('Amounts may not add due to rounding').", "free_cash_flow is derived as cash provided by operating activities less purchases of property, plant and equipment and internal use software. The company does not report a free cash flow measure in these filings.", "Share repurchases: in May 2026 the company paid $2.000 billion under an accelerated share repurchase agreement and received about 40 million shares in total (about 30 million on May 19 and about 10 million at final settlement on June 12, 2026). Treasury shares rose from 263,289,848 at December 31, 2025 to 303,212,284 at September 30, 2026; the 10-Q states that the repurchase reduced the weighted average shares outstanding used to calculate basic and diluted earnings per share. The cash flow statement records the repurchase at $2,000 million, while treasury stock rose by $2,067 million because, per the filing, amounts recorded to treasury stock include excise tax on share repurchases.", "Balance sheet presentation: the Q3 2026 10-Q shows 'Other investments' as its own line ($2,292 million at September 30, 2026; $681 million at December 31, 2025). In the FY2025 10-K that $681 million was part of other long-term assets ($1,866 million = $681 million + $1,185 million as re-presented in the 10-Q). This record carries other_investments only for September 30, 2026 and does not carry other long-term assets, so no figure here is affected. Every other December 31, 2025 line used here appears unchanged in the 10-Q.", "Income taxes: income tax expense for the nine months of 2026 was $132 million on pre-tax income of $2,955 million, against $463 million on $2,685 million a year earlier. The 10-Q attributes part of the nine-month increase in net income to 'a discrete tax benefit recorded in the first quarter of 2026'.", "Dividends: none of the cash flow statements presented shows a dividend paid on common stock.", "Pending acquisition: on January 14, 2026 the company agreed to acquire Penumbra, Inc. (announced January 15, 2026) for $374 per share, approximately $14.500 billion at announcement. As of the Q3 2026 10-Q the transaction had not closed (the FTC issued a Second Request on March 16, 2026; Penumbra stockholders approved it on May 6, 2026) and it is expected to be completed in early 2027. None of the figures here include Penumbra." ], "uncertainties": [ "No three-month cash flow figures are given for Q3 2026 or Q3 2025: the Q3 2026 10-Q prints cash flows only for the nine months ended September 30, and the Q3 2026 earnings release (accession 0000885725-26-000066) prints no cash flow statement. Deriving the quarter would require the six-month figures from the Q2 2026 10-Q, which is not one of the filings this record is built from.", "The trailing-twelve-month figures are arithmetic (fiscal 2025 plus nine months of 2026 less nine months of 2025) on rounded millions, so they can differ by about $1 million from a sum of unrounded amounts; for example, trailing net sales less cost of sales is $14,568 million against the derived trailing gross profit of $14,569 million." ], "headline": { "period": "Q3 FY2026", "period_end_words": "September 30, 2026", "metrics": [ { "label": "Net sales", "format": "usd", "value": 5138000000, "text": "$5.14 billion", "exact": "$5,138,000,000", "compact": "$5.14B", "abs": "$5.14 billion", "prior_value": 5065000000, "prior": "$5.07 billion", "priorabs": "$5.07 billion", "yoy": "up 1.4%", "source": { "array": "quarterly", "field": "income_statement.net_sales", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000885725-26-000070", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000885725-26-000070", "gap_days": 365 } }, { "label": "Net income", "format": "usd", "value": 582000000, "text": "$582 million", "exact": "$582,000,000", "compact": "$582.00M", "abs": "$582 million", "prior_value": 755000000, "prior": "$755 million", "priorabs": "$755 million", "yoy": "down 22.9%", "source": { "array": "quarterly", "field": "income_statement.net_income_attributable_to_common_stockholders", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000885725-26-000070", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000885725-26-000070", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 0.4, "text": "$0.40", "exact": "$0.40", "compact": "$0.40", "abs": "$0.40", "prior_value": 0.51, "prior": "$0.51", "priorabs": "$0.51", "yoy": "down 21.6%", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000885725-26-000070", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000885725-26-000070", "gap_days": 365 } }, { "label": "Electrophysiology net sales", "format": "usd", "value": 816000000, "text": "$816 million", "exact": "$816,000,000", "compact": "$816.00M", "abs": "$816 million", "prior_value": 865000000, "prior": "$865 million", "priorabs": "$865 million", "yoy": "down 5.7%", "source": { "array": "quarterly", "field": "net_sales_by_business.electrophysiology", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000885725-26-000070", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000885725-26-000070", "gap_days": 365 } }, { "label": "Watchman net sales", "format": "usd", "value": 482000000, "text": "$482 million", "exact": "$482,000,000", "compact": "$482.00M", "abs": "$482 million", "prior_value": 512000000, "prior": "$512 million", "priorabs": "$512 million", "yoy": "down 5.9%", "source": { "array": "quarterly", "field": "net_sales_by_business.watchman", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000885725-26-000070", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000885725-26-000070", "gap_days": 365 } } ], "summary": "Boston Scientific reported net sales of $5.14 billion for Q3 FY2026, the quarter ended September 30, 2026, up 1.4% from a year earlier. Net income attributable to common stockholders was $582 million, down 22.9%, or $0.40 per diluted share against $0.51; the company attributed the decline to manufacturing and order-fulfillment disruption and idle-production costs from a cybersecurity incident identified in August, along with higher litigation charges. Electrophysiology sales fell to $816 million and Watchman sales to $482 million, declines the company tied to increased competition in Electrophysiology, a slowing left atrial appendage closure market and the incident.", "qa": [ { "q": "How much revenue did Boston Scientific make in Q3 FY2026?", "a": "Boston Scientific reported net sales of $5.14 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 1.4% from $5.07 billion in the same quarter a year earlier." }, { "q": "Why did Boston Scientific's profit fall in Q3 FY2026?", "a": "Boston Scientific's net income attributable to common stockholders was $582 million in Q3 FY2026, down 22.9% from $755 million a year earlier. The company attributed the decline to manufacturing and order-fulfillment disruption and idle-production costs from a cybersecurity incident identified in August, and to higher litigation charges." }, { "q": "What was Boston Scientific's earnings per share in Q3 FY2026?", "a": "Boston Scientific earned $0.40 per diluted share in Q3 FY2026, the quarter ended September 30, 2026, compared with $0.51 in the same quarter a year earlier." }, { "q": "How did Boston Scientific's Electrophysiology and Watchman sales do in Q3 FY2026?", "a": "Boston Scientific's Electrophysiology net sales were $816 million in Q3 FY2026, down 5.7% from $865 million a year earlier, and Watchman net sales were $482 million, down 5.9% from $512 million. The company cited increased competition in Electrophysiology, a slowing left atrial appendage closure market and disruption from the cybersecurity incident." } ] }, "company_details": { "Name": "Boston Scientific Corp", "Ticker": "BSX", "CIK": "0000885725", "Exchange": "NYSE", "State": "Massachusetts", "Incorporation": "Delaware", "SIC": "3841", "Office": "Industrial Applications and Services", "Industry": "Surgical & Medical Instruments & Apparatus" }, "next_filing": { "predicted_date": "2027-02-16", "predicted_type": "10-K" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "form": "10-Q", "accession": "0000885725-26-000070", "fiscal_year_end": "1231", "source": "facts" }, "source_filings": [ { "role": "annual", "current": false, "form": "10-K", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-02-17", "accession": "0000885725-26-000010", "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "10-Q", "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "filed": "2026-11-02", "accession": "0000885725-26-000070", "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000070/bsx-20260930.htm", "source": "facts" } ], "figure_sources": { "about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '#', and the link is documents[] + '#': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.", "documents": { "d1": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm", "d2": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000070/bsx-20260930.htm" }, "annual": [ { "period_end": "2025-12-31", "income_statement": { "net_sales": "d1#f-57", "cost_of_sales": "d1#f-60", "gross_profit": "d1#f-63", "selling_general_and_administrative_expenses": "d1#f-66", "research_and_development_expenses": "d1#f-69", "royalty_expense": "d1#f-72", "amortization_expense": "d1#f-75", "intangible_asset_impairment_charges": "d1#f-78", "contingent_consideration_net_expense": "d1#f-81", "restructuring_net_charges": "d1#f-84", "litigation_related_net_charges": "d1#f-87", "total_operating_expenses": "d1#f-90", "operating_income": "d1#f-93", "interest_expense": "d1#f-96", "other_income_expense_net": "d1#f-99", "income_before_income_taxes": "d1#f-102", "income_tax_expense": "d1#f-105", "net_income": "d1#f-108", "net_income_attributable_to_noncontrolling_interests": "d1#f-114", "net_income_attributable_to_common_stockholders": "d1#f-117", "basic_shares": "d1#f-126", "diluted_shares": "d1#f-129", "basic_eps": "d1#f-120", "diluted_eps": "d1#f-123" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-162", "trade_accounts_receivable_net": "d1#f-164", "inventories": "d1#f-166", "total_current_assets": "d1#f-172", "property_plant_and_equipment_net": "d1#f-174", "goodwill": "d1#f-176", "other_intangible_assets_net": "d1#f-178", "total_assets": "d1#f-184", "current_debt_obligations": "d1#f-186", "accounts_payable": "d1#f-188", "total_current_liabilities": "d1#f-194", "long_term_debt": "d1#f-196", "deferred_tax_liabilities": "d1#f-1325", "other_long_term_liabilities": "d1#f-200", "total_stockholders_equity": "d1#f-230", "noncontrolling_interests": "d1#f-232", "total_equity": "d1#f-234" }, "cash_flow": { "depreciation_and_amortization": "d1#f-355", "stock_based_compensation": "d1#f-361", "operating_cash_flow": "d1#f-394", "capital_expenditures": "d1#f-397", "acquisitions_of_businesses_net_of_cash_acquired": "d1#f-400", "investments_and_acquisitions_of_certain_technologies": "d1#f-403", "investing_cash_flow": "d1#f-409", "financing_cash_flow": "d1#f-436" }, "net_sales_by_business": { "endoscopy": "d1#f-1758", "urology": "d1#f-1767", "neuromodulation": "d1#f-1776", "interventional_cardiology_and_vascular_therapies": "d1#f-1794", "watchman": "d1#f-1803", "electrophysiology": "d1#f-1812", "cardiac_rhythm_management": "d1#f-1821", "interventional_oncology_and_embolization": "d1#f-1830" }, "net_sales_by_segment": { "medsurg": "d1#f-1785", "cardiovascular": "d1#f-1839" }, "net_sales_by_region": { "united_states": "d1#f-1855", "europe_middle_east_and_africa": "d1#f-1858", "asia_pacific": "d1#f-1861", "latin_america_and_canada": "d1#f-1864" } }, { "period_end": "2024-12-31", "income_statement": { "net_sales": "d1#f-58", "cost_of_sales": "d1#f-61", "gross_profit": "d1#f-64", "selling_general_and_administrative_expenses": "d1#f-67", "research_and_development_expenses": "d1#f-70", "royalty_expense": "d1#f-73", "amortization_expense": "d1#f-76", "intangible_asset_impairment_charges": "d1#f-79", "contingent_consideration_net_expense": "d1#f-82", "restructuring_net_charges": "d1#f-85", "total_operating_expenses": "d1#f-91", "operating_income": "d1#f-94", "interest_expense": "d1#f-97", "other_income_expense_net": "d1#f-100", "income_before_income_taxes": "d1#f-103", "income_tax_expense": "d1#f-106", "net_income": "d1#f-109", "net_income_attributable_to_noncontrolling_interests": "d1#f-115", "net_income_attributable_to_common_stockholders": "d1#f-118", "basic_shares": "d1#f-127", "diluted_shares": "d1#f-130", "basic_eps": "d1#f-121", "diluted_eps": "d1#f-124" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-163", "trade_accounts_receivable_net": "d1#f-165", "inventories": "d1#f-167", "total_current_assets": "d1#f-173", "property_plant_and_equipment_net": "d1#f-175", "goodwill": "d1#f-177", "other_intangible_assets_net": "d1#f-179", "total_assets": "d1#f-185", "current_debt_obligations": "d1#f-187", "accounts_payable": "d1#f-189", "total_current_liabilities": "d1#f-195", "long_term_debt": "d1#f-197", "deferred_tax_liabilities": "d1#f-1326", "other_long_term_liabilities": "d1#f-201", "total_stockholders_equity": "d1#f-231", "noncontrolling_interests": "d1#f-233", "total_equity": "d1#f-235" }, "cash_flow": { "depreciation_and_amortization": "d1#f-356", "stock_based_compensation": "d1#f-362", "operating_cash_flow": "d1#f-395", "capital_expenditures": "d1#f-398", "acquisitions_of_businesses_net_of_cash_acquired": "d1#f-401", "investments_and_acquisitions_of_certain_technologies": "d1#f-404", "investing_cash_flow": "d1#f-410", "financing_cash_flow": "d1#f-437" }, "net_sales_by_business": { "endoscopy": "d1#f-1761", "urology": "d1#f-1770", "neuromodulation": "d1#f-1779", "interventional_cardiology_and_vascular_therapies": "d1#f-1797", "watchman": "d1#f-1806", "electrophysiology": "d1#f-1815", "cardiac_rhythm_management": "d1#f-1824", "interventional_oncology_and_embolization": "d1#f-1671" }, "net_sales_by_segment": { "medsurg": "d1#f-1788", "cardiovascular": "d1#f-1842" }, "net_sales_by_region": { "united_states": "d1#f-1856", "europe_middle_east_and_africa": "d1#f-1859", "asia_pacific": "d1#f-1862", "latin_america_and_canada": "d1#f-1865" } }, { "period_end": "2023-12-31", "income_statement": { "net_sales": "d1#f-59", "cost_of_sales": "d1#f-62", "gross_profit": "d1#f-65", "selling_general_and_administrative_expenses": "d1#f-68", "research_and_development_expenses": "d1#f-71", "royalty_expense": "d1#f-74", "amortization_expense": "d1#f-77", "intangible_asset_impairment_charges": "d1#f-80", "contingent_consideration_net_expense": "d1#f-83", "restructuring_net_charges": "d1#f-86", "litigation_related_net_charges": "d1#f-89", "total_operating_expenses": "d1#f-92", "operating_income": "d1#f-95", "interest_expense": "d1#f-98", "other_income_expense_net": "d1#f-101", "income_before_income_taxes": "d1#f-104", "income_tax_expense": "d1#f-107", "net_income": "d1#f-110", "preferred_stock_dividends": "d1#f-113", "net_income_attributable_to_noncontrolling_interests": "d1#f-116", "net_income_attributable_to_common_stockholders": "d1#f-119", "basic_shares": "d1#f-128", "diluted_shares": "d1#f-131", "basic_eps": "d1#f-122", "diluted_eps": "d1#f-125" }, "cash_flow": { "depreciation_and_amortization": "d1#f-357", "stock_based_compensation": "d1#f-363", "operating_cash_flow": "d1#f-396", "capital_expenditures": "d1#f-399", "acquisitions_of_businesses_net_of_cash_acquired": "d1#f-402", "investments_and_acquisitions_of_certain_technologies": "d1#f-405", "investing_cash_flow": "d1#f-411", "financing_cash_flow": "d1#f-438" }, "net_sales_by_business": { "endoscopy": "d1#f-1764", "urology": "d1#f-1773", "neuromodulation": "d1#f-1782", "interventional_cardiology_and_vascular_therapies": "d1#f-1800", "watchman": "d1#f-1809", "electrophysiology": "d1#f-1818", "cardiac_rhythm_management": "d1#f-1827", "interventional_oncology_and_embolization": "d1#f-1836" }, "net_sales_by_segment": { "medsurg": "d1#f-1791", "cardiovascular": "d1#f-1845" }, "net_sales_by_region": { "united_states": "d1#f-1857", "europe_middle_east_and_africa": "d1#f-1860", "asia_pacific": "d1#f-1863", "latin_america_and_canada": "d1#f-1866" } } ], "quarterly": [ { "period_end": "2026-09-30", "income_statement": { "net_sales": "d2#f-34", "cost_of_sales": "d2#f-38", "gross_profit": "d2#f-42", "selling_general_and_administrative_expenses": "d2#f-46", "research_and_development_expenses": "d2#f-50", "royalty_expense": "d2#f-54", "amortization_expense": "d2#f-58", "intangible_asset_impairment_charges": "d2#f-62", "contingent_consideration_net_expense": "d2#f-66", "restructuring_net_charges": "d2#f-70", "litigation_related_net_charges": "d2#f-74", "total_operating_expenses": "d2#f-78", "operating_income": "d2#f-82", "interest_expense": "d2#f-86", "other_income_expense_net": "d2#f-90", "income_before_income_taxes": "d2#f-94", "income_tax_expense": "d2#f-98", "net_income": "d2#f-102", "net_income_attributable_to_noncontrolling_interests": "d2#f-106", "net_income_attributable_to_common_stockholders": "d2#f-110", "basic_shares": "d2#f-122", "diluted_shares": "d2#f-126", "basic_eps": "d2#f-114", "diluted_eps": "d2#f-118" }, "balance_sheet": { "cash_and_cash_equivalents": "d2#f-170", "trade_accounts_receivable_net": "d2#f-172", "inventories": "d2#f-174", "total_current_assets": "d2#f-180", "other_investments": "d2#f-182", "property_plant_and_equipment_net": "d2#f-976", "goodwill": "d2#f-186", "other_intangible_assets_net": "d2#f-188", "total_assets": "d2#f-194", "current_debt_obligations": "d2#f-196", "accounts_payable": "d2#f-198", "total_current_liabilities": "d2#f-204", "long_term_debt": "d2#f-206", "deferred_tax_liabilities": "d2#f-208", "other_long_term_liabilities": "d2#f-210", "total_stockholders_equity": "d2#f-240", "noncontrolling_interests": "d2#f-242", "total_equity": "d2#f-244" }, "net_sales_by_business": { "endoscopy": "d2#f-1251", "urology": "d2#f-1257", "neuromodulation": "d2#f-1263", "interventional_cardiology_and_vascular_therapies": "d2#f-560", "watchman": "d2#f-1281", "electrophysiology": "d2#f-1287", "cardiac_rhythm_management": "d2#f-1293", "interventional_oncology_and_embolization": "d2#f-1299" }, "net_sales_by_segment": { "medsurg": "d2#f-1269", "cardiovascular": "d2#f-1305" }, "net_sales_by_region": { "united_states": "d2#f-1381", "europe_middle_east_and_africa": "d2#f-1385", "asia_pacific": "d2#f-428", "latin_america_and_canada": "d2#f-1393" } }, { "period_end": "2025-09-30", "income_statement": { "net_sales": "d2#f-35", "cost_of_sales": "d2#f-39", "gross_profit": "d2#f-43", "selling_general_and_administrative_expenses": "d2#f-47", "research_and_development_expenses": "d2#f-51", "royalty_expense": "d2#f-55", "amortization_expense": "d2#f-59", "contingent_consideration_net_expense": "d2#f-67", "restructuring_net_charges": "d2#f-71", "total_operating_expenses": "d2#f-79", "operating_income": "d2#f-83", "interest_expense": "d2#f-87", "other_income_expense_net": "d2#f-91", "income_before_income_taxes": "d2#f-95", "income_tax_expense": "d2#f-99", "net_income": "d2#f-103", "net_income_attributable_to_common_stockholders": "d2#f-111", "basic_shares": "d2#f-123", "diluted_shares": "d2#f-127", "basic_eps": "d2#f-115", "diluted_eps": "d2#f-119" }, "net_sales_by_business": { "endoscopy": "d2#f-1254", "urology": "d2#f-1260", "neuromodulation": "d2#f-1266", "interventional_cardiology_and_vascular_therapies": "d2#f-1278", "watchman": "d2#f-1284", "electrophysiology": "d2#f-1290", "cardiac_rhythm_management": "d2#f-1296", "interventional_oncology_and_embolization": "d2#f-1302" }, "net_sales_by_segment": { "medsurg": "d2#f-1272", "cardiovascular": "d2#f-1308" }, "net_sales_by_region": { "united_states": "d2#f-1382", "europe_middle_east_and_africa": "d2#f-1386", "asia_pacific": "d2#f-1390", "latin_america_and_canada": "d2#f-1394" } } ], "year_to_date": { "income_statement": { "net_sales": "d2#f-36", "cost_of_sales": "d2#f-40", "gross_profit": "d2#f-44", "selling_general_and_administrative_expenses": "d2#f-48", "research_and_development_expenses": "d2#f-52", "royalty_expense": "d2#f-56", "amortization_expense": "d2#f-60", "intangible_asset_impairment_charges": "d2#f-64", "contingent_consideration_net_expense": "d2#f-68", "restructuring_net_charges": "d2#f-72", "litigation_related_net_charges": "d2#f-76", "total_operating_expenses": "d2#f-80", "operating_income": "d2#f-84", "interest_expense": "d2#f-88", "other_income_expense_net": "d2#f-92", "income_before_income_taxes": "d2#f-96", "income_tax_expense": "d2#f-100", "net_income": "d2#f-104", "net_income_attributable_to_noncontrolling_interests": "d2#f-108", "net_income_attributable_to_common_stockholders": "d2#f-112", "basic_shares": "d2#f-124", "diluted_shares": "d2#f-128", "basic_eps": "d2#f-116", "diluted_eps": "d2#f-120" }, "cash_flow": { "depreciation_and_amortization": "d2#f-354", "stock_based_compensation": "d2#f-358", "operating_cash_flow": "d2#f-380", "capital_expenditures": "d2#f-382", "acquisitions_of_businesses_net_of_cash_acquired": "d2#f-384", "investments_and_acquisitions_of_certain_technologies": "d2#f-388", "investing_cash_flow": "d2#f-392", "repurchase_of_common_stock": "d2#f-406", "financing_cash_flow": "d2#f-412" }, "net_sales_by_business": { "endoscopy": "d2#f-1317", "urology": "d2#f-1323", "neuromodulation": "d2#f-1329", "interventional_cardiology_and_vascular_therapies": "d2#f-1341", "watchman": "d2#f-1347", "electrophysiology": "d2#f-1353", "cardiac_rhythm_management": "d2#f-1359", "interventional_oncology_and_embolization": "d2#f-1365" }, "net_sales_by_segment": { "medsurg": "d2#f-1335", "cardiovascular": "d2#f-1371" }, "net_sales_by_region": { "united_states": "d2#f-1383", "europe_middle_east_and_africa": "d2#f-1387", "asia_pacific": "d2#f-1391", "latin_america_and_canada": "d2#f-1395" }, "prior_year_comparative": { "income_statement": { "net_sales": "d2#f-37", "cost_of_sales": "d2#f-41", "gross_profit": "d2#f-45", "selling_general_and_administrative_expenses": "d2#f-49", "research_and_development_expenses": "d2#f-53", "royalty_expense": "d2#f-57", "amortization_expense": "d2#f-61", "intangible_asset_impairment_charges": "d2#f-65", "contingent_consideration_net_expense": "d2#f-69", "restructuring_net_charges": "d2#f-73", "total_operating_expenses": "d2#f-81", "operating_income": "d2#f-85", "interest_expense": "d2#f-89", "other_income_expense_net": "d2#f-93", "income_before_income_taxes": "d2#f-97", "income_tax_expense": "d2#f-101", "net_income": "d2#f-105", "net_income_attributable_to_noncontrolling_interests": "d2#f-109", "net_income_attributable_to_common_stockholders": "d2#f-113", "basic_shares": "d2#f-125", "diluted_shares": "d2#f-129", "basic_eps": "d2#f-117", "diluted_eps": "d2#f-121" }, "cash_flow": { "depreciation_and_amortization": "d2#f-355", "stock_based_compensation": "d2#f-359", "operating_cash_flow": "d2#f-381", "capital_expenditures": "d2#f-383", "acquisitions_of_businesses_net_of_cash_acquired": "d2#f-385", "investments_and_acquisitions_of_certain_technologies": "d2#f-389", "investing_cash_flow": "d2#f-393", "financing_cash_flow": "d2#f-413" }, "net_sales_by_business": { "endoscopy": "d2#f-1320", "urology": "d2#f-1326", "neuromodulation": "d2#f-1332", "interventional_cardiology_and_vascular_therapies": "d2#f-1344", "watchman": "d2#f-1350", "electrophysiology": "d2#f-1356", "cardiac_rhythm_management": "d2#f-1362", "interventional_oncology_and_embolization": "d2#f-1368" }, "net_sales_by_segment": { "medsurg": "d2#f-1338", "cardiovascular": "d2#f-1374" }, "net_sales_by_region": { "united_states": "d2#f-1384", "europe_middle_east_and_africa": "d2#f-1388", "asia_pacific": "d2#f-1392", "latin_america_and_canada": "d2#f-1396" } } } } }